Clinical Trial

Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

Study acronym: TAPER
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2026-01-15; most recent amendment 2026-06-24.
Status change: Not Yet Recruiting → Recruiting 2026-02-04
Trial Details
NCT Number NCT07363642
Lead Sponsor AstraZeneca
Conditions Severe Asthma
Enrollment 400 participants
Start Date 2026-01-28
Primary Completion 2027-08-07 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-25